BAFF activates the AKT/BCL10/BCL3 signaling transduction pathway. (A) BAFF treatment increases levels of TNF-α, BCL10, NF-κB p65, and BAFF. Whole-cell lysates of BAFF-treated Pfeiffer cells were subjected to immunoblotting (IB) using anti–TNF-α, anti–BCL10, anti–NF-κB p65, and anti-BAFF antibodies to show the total amount of protein. (B) BAFF increases levels of c-myc and cyclin D3 (the downstream genes of NF-κB), but not cyclin D1 and BCL-2. Actin stain was used as a loading control.